{
  "topic": {
    "stem": "MIRVETUXIMAB_OVARIAN_REVIEW",
    "name": "Mirvetuximab soravtansine FRα+ ovarian",
    "ncts": [
      "NCT04209855",
      "NCT04296890"
    ],
    "drug_patterns": [
      "mirvetuximab"
    ],
    "condition_patterns": [
      "ovarian"
    ]
  },
  "trials": [
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": true,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04209855",
        "aact_title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression",
        "aact_acronym": "MIRASOL",
        "start_date": "2019-12-31",
        "primary_completion_date": "2023-03-06",
        "aact_intvs": [
          "Mirvetuximab Soravtansine",
          "Paclitaxel",
          "Topotecan",
          "Pegylated liposomal doxorubicin"
        ],
        "aact_conditions": [
          "epithelial ovarian cancer",
          "fallopian tube cancer",
          "peritoneal cancer"
        ],
        "pmid": "40179908",
        "pubmed_year": 2025,
        "pubmed_doi": "10.1016/S1470-2045(25)00021-X",
        "aact_per_arm_counts": {
          "BG000": 227,
          "BG001": 226
        },
        "aact_primary_outcome_measure": "Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",
        "aact_outcome_count_rows": [
          [
            "OG000",
            "41.9"
          ],
          [
            "OG001",
            "15.9"
          ],
          [
            "OG000",
            "34.0"
          ],
          [
            "OG001",
            "23.0"
          ],
          [
            "OG000",
            "211.0"
          ],
          [
            "OG001",
            "194.0"
          ],
          [
            "OG000",
            "58.0"
          ],
          [
            "OG001",
            "30.1"
          ]
        ]
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04296890",
        "aact_title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression",
        "aact_acronym": "SORAYA",
        "start_date": "2020-07-23",
        "primary_completion_date": "2021-11-16",
        "aact_intvs": [
          "Mirvetuximab Soravtansine"
        ],
        "aact_conditions": [
          "epithelial ovarian cancer",
          "fallopian tube cancer",
          "peritoneal cancer"
        ],
        "pmid": "38858103",
        "pubmed_year": 2024,
        "pubmed_doi": "10.1136/ijgc-2024-005401",
        "aact_per_arm_counts": {
          "BG000": 106
        },
        "aact_primary_outcome_measure": "Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
        "aact_outcome_count_rows": [
          [
            "OG000",
            "32.4"
          ],
          [
            "OG000",
            "46.5"
          ],
          [
            "OG000",
            "105.0"
          ]
        ]
      }
    }
  ],
  "gate_summary": {
    "A_aact_exists": 2,
    "B_drug_in_intvs": 2,
    "C_condition_in_aact": 2,
    "D_pmid_topic_match": 2,
    "E_two_arms": 1,
    "F_primary_outcome_known": 2
  },
  "n_total": 2,
  "n_pass_all": 1,
  "pass_rate": 0.5,
  "verdict": "VIABLE"
}